6518 related articles for article (PubMed ID: 19110742)
21. Topical imiquimod immunotherapy in the management of lentigo maligna.
Powell AM; Russell-Jones R; Barlow RJ
Clin Exp Dermatol; 2004 Jan; 29(1):15-21. PubMed ID: 14723712
[TBL] [Abstract][Full Text] [Related]
22. Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study.
Gautschi M; Oberholzer PA; Baumgartner M; Gadaldi K; Yawalkar N; Hunger RE
J Am Acad Dermatol; 2016 Jan; 74(1):81-87.e1. PubMed ID: 26601565
[TBL] [Abstract][Full Text] [Related]
23. Lentigo maligna successfully treated with imiquimod.
du Plessis PJ
S Afr J Surg; 2007 May; 45(2):72. PubMed ID: 17674567
[No Abstract] [Full Text] [Related]
24. Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production.
Martires KJ; Capaldi L; Pattee SF; Maloney ME; Bordeaux JS
Arch Dermatol; 2010 Sep; 146(9):1047-8. PubMed ID: 20855714
[No Abstract] [Full Text] [Related]
25. In vivo reflectance confocal microscopy to monitor the response of lentigo maligna to imiquimod.
Alarcon I; Carrera C; Alos L; Palou J; Malvehy J; Puig S
J Am Acad Dermatol; 2014 Jul; 71(1):49-55. PubMed ID: 24725478
[TBL] [Abstract][Full Text] [Related]
26. Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate.
Kirtschig G; van Meurs T; van Doorn R
Acta Derm Venereol; 2015 Jan; 95(1):83-5. PubMed ID: 24696093
[TBL] [Abstract][Full Text] [Related]
27. Periocular lentigo maligna treated with imiquimod.
O'Neill J; Ayers D; Kenealy J
J Dermatolog Treat; 2011 Apr; 22(2):109-12. PubMed ID: 20666668
[TBL] [Abstract][Full Text] [Related]
28. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy.
Powell AM; Russell-Jones R
J Am Acad Dermatol; 2004 May; 50(5):792-6. PubMed ID: 15097969
[TBL] [Abstract][Full Text] [Related]
29. Imiquimod as an antiaging agent.
Metcalf S; Crowson AN; Naylor M; Haque R; Cornelison R
J Am Acad Dermatol; 2007 Mar; 56(3):422-5. PubMed ID: 17184874
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment.
Tio DCKS; van Montfrans C; Ruijter CGH; Hoekzema R; Bekkenk MW
Acta Derm Venereol; 2019 Sep; 99(10):884-888. PubMed ID: 31233181
[TBL] [Abstract][Full Text] [Related]
31. Imiquimod in the treatment of lentigo maligna.
Rajpar SF; Marsden JR
Br J Dermatol; 2006 Oct; 155(4):653-6. PubMed ID: 16965411
[TBL] [Abstract][Full Text] [Related]
32. Topical imiquimod for periocular lentigo maligna.
Demirci H; Shields CL; Bianciotto CG; Shields JA
Ophthalmology; 2010 Dec; 117(12):2424-9. PubMed ID: 20591492
[TBL] [Abstract][Full Text] [Related]
33. Topical imiquimod therapy for lentigo maligna.
Mahoney MH; Joseph MG; Temple C
Ann Plast Surg; 2008 Oct; 61(4):419-24. PubMed ID: 18812714
[TBL] [Abstract][Full Text] [Related]
34. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
[TBL] [Abstract][Full Text] [Related]
35. Image in clinical medicine. Lentigo maligna.
Noel B; Kunzle N
N Engl J Med; 2005 Nov; 353(20):2176. PubMed ID: 16291987
[No Abstract] [Full Text] [Related]
36. Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod.
Woodmansee CS; McCall MW
Dermatol Surg; 2009 Aug; 35(8):1286-9. PubMed ID: 19438661
[No Abstract] [Full Text] [Related]
37. Confocal Microscopy and Lentigo Maligna: An in vivo Pilot Study for the Assessment of Response to Imiquimod Therapy.
Brand FL; Seyed Jafari SM; Hunger RE
Dermatology; 2019; 235(2):150-155. PubMed ID: 30554198
[TBL] [Abstract][Full Text] [Related]
38. Amelanotic lentigo maligna managed with topical imiquimod.
Lapresta A; García-Almagro D; Sejas AG
J Dermatol; 2012 May; 39(5):503-5. PubMed ID: 21973079
[No Abstract] [Full Text] [Related]
39. [Imiquimod in the treatment of lentigo maligna].
Nagore E; Botella-Estrada R
Actas Dermosifiliogr; 2011 Oct; 102(8):559-62. PubMed ID: 21536245
[No Abstract] [Full Text] [Related]
40. Five-year recurrence rate of lentigo maligna after treatment with imiquimod.
Kai AC; Richards T; Coleman A; Mallipeddi R; Barlow R; Craythorne EE
Br J Dermatol; 2016 Jan; 174(1):165-8. PubMed ID: 26595446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
